Active Clinical Trials

Dasatinib in Resectable Malignant Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Malignant Pleural Mesothelioma

Estimated Enrollment: 60

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 2006-0935|NCI-2010-01505|W81XWH-07-1-0306

Study First Received: March 27, 2008

Last Updated: September 23, 2016

Estimated Primary Completion Date: March 2018

 

Primary Outcome Measures:

Modulation of biomarker p-Src Tyr419 expression|Progression-free Survival

Sponsors and Collaborators:

M.D. Anderson Cancer Center|Bristol-Myers Squibb|United States Department of Defense

Website Link: https://ClinicalTrials.gov/show/NCT00652574

Leave a Reply

Call Now